Last updated: 24 January 2022 at 5:05pm EST

William J Garner Net Worth




The estimated Net Worth of William J Garner is at least $804 millier dollars as of 16 July 2015. William Garner owns over 16,666 units of InMed Pharmaceuticals stock worth over $700,410 and over the last 11 years William sold INM stock worth over $104,000.

William Garner INM stock SEC Form 4 insiders trading

William has made over 3 trades of the InMed Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently William bought 16,666 units of INM stock worth $10,000 on 16 July 2015.

The largest trade William's ever made was selling 80,000 units of InMed Pharmaceuticals stock on 18 March 2014 worth over $104,000. On average, William trades about 12,708 units every 83 days since 2013. As of 16 July 2015 William still owns at least 2,415,207 units of InMed Pharmaceuticals stock.

You can see the complete history of William Garner stock trades at the bottom of the page.



What's William Garner's mailing address?

William's mailing address filed with the SEC is C/O INMED PHARMACEUTICALS INC., 310-815 WEST HASTINGS ST., VANCOUVER, A1, V6C1B4.

Insiders trading at InMed Pharmaceuticals

Over the last 4 years, insiders at InMed Pharmaceuticals have traded over $43 worth of InMed Pharmaceuticals stock and bought 153,613 units worth $127,277 . The most active insiders traders include William J Garner, Eric A Adams et Andrew Hull. On average, InMed Pharmaceuticals executives and independent directors trade stock every 86 days with the average trade being worth of $3,718. The most recent stock trade was executed by Alexandra Diane Janet Mancini on 31 July 2024, trading 240 units of INM stock currently worth $43.



What does InMed Pharmaceuticals do?

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.



What does InMed Pharmaceuticals's logo look like?

InMed Pharmaceuticals Inc. logo

Complete history of William Garner stock trades at DelMar Pharmaceuticals et InMed Pharmaceuticals

Date
#
Société
Initié
Trans.
Transaction
Actions Prix par action Prix ​​total Actions après Source
16 Jul 2015 William J Garner
Directeur
Acheter 16,666 $0.60 $10,000
16 Jul 2015
2,415,207
18 Mar 2014 William J Garner
Directeur
Vente 80,000 $1.30 $104,000
18 Mar 2014
10,000
20 Sep 2013 William J Garner
Directeur
Acheter 5,000 $1.00 $5,000
20 Sep 2013
5,000


InMed Pharmaceuticals executives and stock owners

InMed Pharmaceuticals executives and other stock owners filed with the SEC include: